Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

Slides:

Advertisements

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Advertisements

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

End point Net change with soy supplements vs control (95% CI) p

Chapter 28 Nutrition, Lifestyle, and Hypertension

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

Time-course changes in blood glucose (BG; A), C peptide (B), and non-esterified fatty acid (NEFA; C) levels. Time-course changes in blood glucose (BG;

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Changes in BG levels from 60 min (immediately before the first stair climbing–descending exercise (ST-EX)) to 180 min postmeal. Changes in BG levels from.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Suggested pathway for discussions between healthcare professionals and people with diabetes intending to fast during Ramadan. CBG, capillary blood glucose; DVLA,

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Calibration plot by quintiles of predicted 5-year diabetes risk of the comprehensive German Diabetes Risk Score (GDRS) for prediction of incident diagnosed.

Age-standardized probability of finding undiagnosed diabetes among the US population without diagnosed diabetes aged ≥18 years by survey cycle. Age-standardized.

Categorisation of subjects in four groups according to median values of left ventricular end-diastolic volume (LVEDV) mL/m2 and E/e′. Categorisation of.

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

Plasma adiponectin levels by race/ethnicity (1A) and gender (1B) among study participants who developed prediabetes/diabetes (Progressors, P) compared.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Exercise PA in MET-hours/week versus total leisure sedentary behavior in hours/day and incident type 2 diabetes mellitus from 2000 to Exercise PA.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

(A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.

Age-adjusted and sex-adjusted prevalence of diabetes of Asian immigrants and whites in California from 2003 to Age-adjusted and sex-adjusted prevalence.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment.

Difference in the prevalence of sarcopenia and its components (low muscle strength and low muscle mass) between NDR, NPDR and PDR. NDR, no diabetic retinopathy;

Sensitivity analysis: random-effects model of the risk of lower extremity amputation (LEA) in people with diabetes associated with depression compared.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.

Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.

Participant flow diagram for the ‘GNHIES98—longitudinal sample’ and the ‘DEGS1—cross-sectional sample’. Participant flow diagram for the ‘GNHIES98—longitudinal.

Serum adiponectin is significantly lower in obese gestational diabetes mellitus (GDM) women compared with obese women at 26 weeks of gestation. Serum adiponectin.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Stages of change for physical activity and dietary habits and associations with self-management scores (A) and HRQL scores (B). heiQ, Health Education.

Mean decline in grip strength with aging is shown for participants categorized by baseline quartile of 2 h glucose (2HG). Mean decline in grip strength.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Presentation transcript:

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. All participants, N=129. Group A, n=61 (participants maintained <7% weight loss at 1 year). Group B, n=68 (participants maintained ≥7% weight loss at 1 year). *p<0.05, **p<0.01, ***p<0.001 (group A vs group B). Osama Hamdy et al. BMJ Open Diab Res Care 2017;5:e000259 ©2017 by American Diabetes Association